IRLAB Therapeutics has announced that the final patient has completed the treatment period and follow-up visit in the Phase IIb study of mesdopetam in levodopa-induced dyskinesia in people with Parkinson’s disease (PD-LIDs).
The top-line results are expected to be reported in mid-January 2023, states the company in a press release.
An oral dopamine D3 antagonist
Mesdopetam, an oral dopamine D3 antagonist, is being developed in partnership with Ipsen as a treatment for Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs), a severe form of troublesome involuntary movements commonly occurring in Parkinson’s disease. The Phase IIb study of mesdopetam is a randomized, double-blind, placebo-controlled study with the aim of evaluating the efficacy, safety and, optimal dose of mesdopetam in people with PD-LIDs.
“The final stages of this important trial, for what could be a major breakthrough in treating this severe unmet need in Parkinson’s disease are now underway.”
The study randomized 156 patients distributed across four groups, three dose levels of mesdopetam and a placebo group with approximately 40 patients in each group with a treatment period of three months. The study was conducted at 46 study sites in Europe, Israel and in the US.
“The final stages of this important trial, for what could be a major breakthrough in treating this severe unmet need in Parkinson’s disease are now underway,” says Richard Godfrey, Chief Executive Officer, IRLAB.
The global specialty pharma company Ipsen holds the exclusive right for further clinical development and commercialization of the mesdopetam program in PD-LIDs and potentially other indications.
Photo: IRLAB
